BR112022000755A2 - Combinação, composição farmacêutica, kit para uso no tratamento de câncer, uso, método para o tratamento de câncer, e, teste diagnóstico para determinar se um paciente se beneficiará do tratamento - Google Patents

Combinação, composição farmacêutica, kit para uso no tratamento de câncer, uso, método para o tratamento de câncer, e, teste diagnóstico para determinar se um paciente se beneficiará do tratamento

Info

Publication number
BR112022000755A2
BR112022000755A2 BR112022000755A BR112022000755A BR112022000755A2 BR 112022000755 A2 BR112022000755 A2 BR 112022000755A2 BR 112022000755 A BR112022000755 A BR 112022000755A BR 112022000755 A BR112022000755 A BR 112022000755A BR 112022000755 A2 BR112022000755 A2 BR 112022000755A2
Authority
BR
Brazil
Prior art keywords
treating cancer
treatment
patient
benefit
diagnostic test
Prior art date
Application number
BR112022000755A
Other languages
English (en)
Inventor
Björn Frendéus
Ingrid Karlsson
Ingrid Teige
Linda Mårtensson
Mark Cragg
Robert Oldham
Stephen Beers
Original Assignee
Bioinvent Int Ab
Univ Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent Int Ab, Univ Southampton filed Critical Bioinvent Int Ab
Publication of BR112022000755A2 publication Critical patent/BR112022000755A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

combinação, composição farmacêutica, kit para uso no tratamento de câncer, uso, método para o tratamento de câncer, e, teste diagnóstico para determinar se um paciente se beneficiará do tratamento.trata-se do uso combinado de uma primeira molécula de anticorpo que se liga especificamente a fc¿riib por meio de sua região fab e que se liga a um receptor fey por meio de sua região fc, e uma segunda molécula de anticorpo que se liga especificamente a pd-1 e que se liga a pelo menos um receptor fey por meio de sua região fc, no tratamento de câncer em um paciente com linfócitos t que se infiltram em tumor com uma expressão de pd-1 média ou alta, bem como composições farmacêuticas e kits compreendendo essas duas moléculas de anticorpo e métodos de tratamento de câncer usando esses dois anticorpos. é descrito também um teste de diagnóstico para identificação de pacientes que se beneficiam do tratamento aqui descrito.
BR112022000755A 2019-07-17 2020-07-17 Combinação, composição farmacêutica, kit para uso no tratamento de câncer, uso, método para o tratamento de câncer, e, teste diagnóstico para determinar se um paciente se beneficiará do tratamento BR112022000755A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19186840 2019-07-17
PCT/EP2020/070319 WO2021009358A1 (en) 2019-07-17 2020-07-17 Antibody combinations for treatment of cancer in specific patients

Publications (1)

Publication Number Publication Date
BR112022000755A2 true BR112022000755A2 (pt) 2022-03-15

Family

ID=67402874

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000755A BR112022000755A2 (pt) 2019-07-17 2020-07-17 Combinação, composição farmacêutica, kit para uso no tratamento de câncer, uso, método para o tratamento de câncer, e, teste diagnóstico para determinar se um paciente se beneficiará do tratamento

Country Status (12)

Country Link
US (1) US20220259309A1 (pt)
EP (1) EP3999186A1 (pt)
JP (1) JP2022541249A (pt)
KR (1) KR20220035150A (pt)
CN (1) CN114127119A (pt)
AU (1) AU2020315163A1 (pt)
BR (1) BR112022000755A2 (pt)
CA (1) CA3147164A1 (pt)
IL (1) IL289787A (pt)
MX (1) MX2022000657A (pt)
TW (1) TW202116807A (pt)
WO (1) WO2021009358A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272389A (en) * 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
JP2024509944A (ja) 2021-03-09 2024-03-05 バイオインヴェント インターナショナル アーベー 抗体の新規の組み合わせ及びその使用
WO2023070100A1 (en) * 2021-10-21 2023-04-27 Seismic Therapeutic, Inc. Dual targeted immune regulating compositions
TW202336033A (zh) 2022-03-07 2023-09-16 瑞典商生物創新國際有限公司 抗體之新穎組合及用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2981543A1 (en) * 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
US10669338B2 (en) * 2016-06-17 2020-06-02 Immunomedics, Inc. Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
CN108659112B (zh) * 2017-03-30 2021-01-26 上海市同济医院 一种非对称双特异性抗体
CA3065171A1 (en) * 2017-06-05 2018-12-13 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical ch2-ch3 region mutations
US20200362036A1 (en) * 2018-01-10 2020-11-19 Bioinvent International Ab Novel combination and use of antibodies

Also Published As

Publication number Publication date
KR20220035150A (ko) 2022-03-21
JP2022541249A (ja) 2022-09-22
US20220259309A1 (en) 2022-08-18
CA3147164A1 (en) 2021-01-21
IL289787A (en) 2022-03-01
MX2022000657A (es) 2022-05-18
EP3999186A1 (en) 2022-05-25
AU2020315163A1 (en) 2022-02-03
WO2021009358A1 (en) 2021-01-21
TW202116807A (zh) 2021-05-01
CN114127119A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
BR112022000755A2 (pt) Combinação, composição farmacêutica, kit para uso no tratamento de câncer, uso, método para o tratamento de câncer, e, teste diagnóstico para determinar se um paciente se beneficiará do tratamento
Komori et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
Orsolini et al. Titer-dependent effect of anti-citrullinated protein antibodies on systemic bone mass in rheumatoid arthritis patients
Wallwiener et al. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
Crawford et al. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?
Quinn et al. Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis
BRPI0619748B8 (pt) anticorpo monoclonal, polinucleotídeo, composição, mistura, uso de um anticorpo monoclonal ou uma parte funcional do mesmo, método para preparar uma composição farmacêutica, linhagem celular de hibridoma isolado, método de diagnóstico de uma doença ou condição associada a amilóide em um paciente, método para diagnosticar uma predisposição para uma doença ou condição, método para monitorar doença residual mínima, método para prever a responsividade de um paciente e kits de teste
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
Sugie et al. Characterization of dermatomyositis with coexistence of anti-Jo-1 and anti-SRP antibodies
Adamski et al. Dormant glioblastoma cells acquire stem cell characteristics and are differentially affected by Temozolomide and AT101 treatment
Bhatt et al. Central nervous system complications and outcomes after allogeneic hematopoietic stem cell transplantation
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
An et al. High CXC chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma
BRPI0706575B8 (pt) uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado.
Bjelica et al. One‐year follow‐up study of neuropathic pain in chronic inflammatory demyelinating polyradiculoneuropathy
Baban et al. Status of stem cells in diabetic nephropathy: predictive and preventive potentials
BR112021019524A2 (pt) Uso de anticorpo anti-pd-1 na preparação de medicamento para tratamento de tumores sólidos
Chun et al. Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
Zamora-Ortiz et al. Poor performance of the total kappa/lambda light chain quantification in the diagnosis and follow-up of patients with multiple myeloma
Coiffier Standard treatment of advanced-stage diffuse large B-cell lymphoma
BRPI0610267B8 (pt) métodos de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero, e, uso do método
Fontana et al. Multitracer approach to understanding the complexity of reactive astrogliosis in Alzheimer’s brains
BR112022022045A2 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd103 humano, um ou mais ácidos nucleicos, sistema de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou fragmento de ligação ao antígeno, para detectar a presença de cd103 em uma amostra biológica, para tratar ou prevenir uma condição mediada por sinalização de cd103 em um indivíduo em necessidade, para inibir a sinalização de cd103 em uma célula, para inibir a ligação de cd103 à e-caderina presente em uma célula, para retirar as células que expressam cd103 em um indivíduo, para tratar ou prevenir uma doença e agente de imageamento